20/20 HealthCare Partners
  • Home
  • Strategic Partners
  • Team
  • Companies
  • News
  • Contact

20/20 HealthCare Partners

07 Nov2019

SQZ Biotech and AskBio Announce Research Collaboration to Create Immune Tolerization Products for AAV Gene Therapies

Written by 2020HCP.com. Posted in News

Scientific leaders in cell and gene therapy collaborate to determine efficacy of SQZ tolerizing antigen carriers (TACs) containing AAV components to overcome patient immune responses to AAV
  • Continue Reading
06 Nov2019

Variantyx Launches Its Whole Genome Sequencing (WGS)-Based In-Silico Panel Program at National Society of Genetic Counselors Annual Conference

Written by 2020HCP.com. Posted in News

FRAMINGHAM, Mass.–(BUSINESS WIRE)–Variantyx today announced the launch of its in-silico panel program which is an extension of its Genomic Unity™ whole genome sequencing (WGS)-based testing service. Available to clinicians since 2017, Genomic Unity™ has been instrumental in resolving many complex patient cases. It pairs the patient’s complete DNA sequence with proprietary data analysis algorithms to detect genome-wide small sequence changes, structural variants, mitochondrial variants and tandem repeat expansions – all within a single assay.
  • Continue Reading
05 Nov2019

SQZ Biotech to Present First Time Data Demonstrating Potential of Company’s Second Novel Cell Therapy Approach in Oncology – Activating Antigen Carriers (AACs)

Written by 2020HCP.com. Posted in News

Preclinical data demonstrate SQZ AACs ability to prime antigen-specific T cell responses and drive tumor reduction in vivo
SQZ to also present additional preclinical data on company’s first oncology approach with SQZPBMC-HPV
WATERTOWN, Mass., Nov. 5, 2019 — SQZ Biotechnologies (SQZ), a clinical stage cell therapy company developing innovative treatments for multiple therapeutic areas, today announced the first data highlighting the potential of the company’s activating antigen carrier (AAC) immunotherapy program for oncology indications. The findings will be detailed in a poster presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting. SQZ AACs are part of SQZ’s immune-oncology pipeline, which also includes SQZ Antigen Presenting Cells (APCs).
  • Continue Reading
22 Oct2019

SQZ Biotech Announces Clearance of US IND Application for First Clinical Trial

Written by 2020HCP.com. Posted in News

First program advancing into the clinic through the SQZ-Roche collaboration in APCs for oncology
WATERTOWN, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) — SQZ Biotechnologies (SQZ), a cell therapy company developing innovative treatments for multiple therapeutic areas, today announced that the company’s Investigational New Drug (IND) application for SQZ-PBMC-HPV, a novel cellular immunotherapy of antigen presenting cells (APCs) has been cleared after submission to the U.S. Food and Drug Administration (FDA).
  • Continue Reading
21 Oct2019

Verseau Launches with $50 Million to Develop First-in-Class Macrophage-Targeted Immunotherapies and Appoints George Golumbeski as Chairman of the Board

Written by 2020HCP.com. Posted in News

BEDFORD Mass., October 21, 2019 — Verseau Therapeutics, Inc. (“Verseau”) launched today with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital.
  • Continue Reading
  • 1
  • 2
  • 3
  • 4
  • 5

Latest News

  • SQZ Biotech and AskBio Announce Research Collaboration to Create Immune Tolerization Products for AAV Gene Therapies November 7, 2019
  • Variantyx Launches Its Whole Genome Sequencing (WGS)-Based In-Silico Panel Program at National Society of Genetic Counselors Annual Conference November 6, 2019
  • SQZ Biotech to Present First Time Data Demonstrating Potential of Company’s Second Novel Cell Therapy Approach in Oncology – Activating Antigen Carriers (AACs) November 5, 2019
  • SQZ Biotech Announces Clearance of US IND Application for First Clinical Trial October 22, 2019
  • Verseau Launches with $50 Million to Develop First-in-Class Macrophage-Targeted Immunotherapies and Appoints George Golumbeski as Chairman of the Board October 21, 2019

20/20 HealthCare Partners | 2000 Commonwealth Ave, Suite 200, Auburndale, MA 02466 | Contact Us

Copyright © 2019
  • Home
  • Strategic Partners
  • Team
  • Companies
  • News
  • Contact